Activity ratios measure how efficiently a company performs day-to-day tasks, such us the collection of receivables and management of inventory.
Short-term Activity Ratios (Summary)
Turnover Ratios
Average No. Days
Based on: 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31).
The operating activity ratios indicate a general improvement in asset utilization and credit management between 2018 and 2022, characterized by a more efficient receivables cycle and stable payables management.
- Receivables Management
- Receivables turnover exhibited an overall upward trajectory, increasing from 4.35 in 2018 to 4.94 in 2022, with a peak of 5.44 in 2021. This improvement is reflected in the average receivable collection period, which declined from 84 days in 2018 to 74 days in 2022, reaching a minimum of 67 days in 2021. These patterns suggest an enhanced capacity to convert credit sales into cash more rapidly over the analyzed period.
- Payables Management
- Payables turnover showed moderate fluctuation, beginning at 15.44 in 2018, dipping to a low of 12.70 in 2019, and stabilizing at 14.55 by 2022. Correspondingly, the average payables payment period remained relatively consistent, ranging between 24 and 29 days. This stability indicates a disciplined and predictable approach to settling obligations with suppliers.
- Working Capital Efficiency
- Working capital turnover demonstrated significant volatility during the years for which information was available. A substantial spike occurred in 2019, reaching 61.26, before declining sharply to 21.35 in 2020. Such variance suggests inconsistent efficiency in the utilization of net current assets to generate revenue during that specific interval.
AI Ask an analyst for more
Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.
Without a user account, I tend to respond rather slowly.
How can I help you?
Receivables Turnover
| Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | ||
|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | ||||||
| Revenues | 14,410) | 13,874) | 11,359) | 11,088) | 10,412) | |
| Trade accounts receivable and unbilled services, net | 2,917) | 2,551) | 2,410) | 2,582) | 2,394) | |
| Short-term Activity Ratio | ||||||
| Receivables turnover1 | 4.94 | 5.44 | 4.71 | 4.29 | 4.35 | |
| Benchmarks | ||||||
| Receivables Turnover, Competitors2 | ||||||
| AbbVie Inc. | 5.16 | 5.63 | — | — | — | |
| Amgen Inc. | 4.46 | 4.96 | — | — | — | |
| Bristol-Myers Squibb Co. | 5.48 | 5.65 | — | — | — | |
| Danaher Corp. | 6.40 | 6.36 | — | — | — | |
| Eli Lilly & Co. | 4.14 | 4.24 | — | — | — | |
| Gilead Sciences Inc. | 5.65 | 6.01 | — | — | — | |
| Johnson & Johnson | 5.88 | 6.14 | — | — | — | |
| Merck & Co. Inc. | 6.27 | 5.28 | — | — | — | |
| Pfizer Inc. | 9.24 | 7.16 | — | — | — | |
| Regeneron Pharmaceuticals Inc. | 2.28 | 2.66 | — | — | — | |
| Thermo Fisher Scientific Inc. | 5.53 | 4.92 | — | — | — | |
| Vertex Pharmaceuticals Inc. | 6.19 | 6.66 | — | — | — | |
| Receivables Turnover, Sector | ||||||
| Pharmaceuticals, Biotechnology & Life Sciences | 5.76 | 5.54 | — | — | — | |
| Receivables Turnover, Industry | ||||||
| Health Care | 8.22 | 8.00 | — | — | — | |
Based on: 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31).
1 2022 Calculation
Receivables turnover = Revenues ÷ Trade accounts receivable and unbilled services, net
= 14,410 ÷ 2,917 = 4.94
2 Click competitor name to see calculations.
Between 2018 and 2022, total revenues exhibited a consistent upward trajectory, growing from US$ 10,412 million to US$ 14,410 million. During this same period, trade accounts receivable and unbilled services, net, increased from US$ 2,394 million to US$ 2,917 million. Although both metrics grew, the growth in revenues generally outpaced the increase in receivables, influencing the efficiency of the collection cycle.
- Receivables Turnover Performance
- The receivables turnover ratio showed a general improvement from 2019 to 2021, moving from 4.29 to a peak of 5.44. This progression indicates an enhanced ability to convert credit sales into cash. However, a decline to 4.94 was observed in 2022, occurring alongside the period's highest recorded net receivables balance of US$ 2,917 million.
- Operational Efficiency Trends
- The peak turnover ratio in 2021 suggests the highest level of operational efficiency in managing receivables over the five-year period. The subsequent decrease in 2022 indicates a slight deceleration in the collection process, though the ratio remains higher than the levels recorded between 2018 and 2020, suggesting a net improvement in long-term collection efficiency.
AI Ask an analyst for more
Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.
Without a user account, I tend to respond rather slowly.
How can I help you?
Payables Turnover
| Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | ||
|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | ||||||
| Cost of revenues, exclusive of depreciation and amortization | 9,382) | 9,233) | 7,500) | 7,300) | 6,746) | |
| Accounts payable | 645) | 621) | 581) | 575) | 437) | |
| Short-term Activity Ratio | ||||||
| Payables turnover1 | 14.55 | 14.87 | 12.91 | 12.70 | 15.44 | |
| Benchmarks | ||||||
| Payables Turnover, Competitors2 | ||||||
| AbbVie Inc. | 5.94 | 6.05 | — | — | — | |
| Amgen Inc. | 4.08 | 4.72 | — | — | — | |
| Bristol-Myers Squibb Co. | 3.33 | 3.37 | — | — | — | |
| Danaher Corp. | 5.45 | 4.48 | — | — | — | |
| Eli Lilly & Co. | 3.43 | 4.38 | — | — | — | |
| Gilead Sciences Inc. | 6.25 | 9.36 | — | — | — | |
| Johnson & Johnson | 2.66 | 2.70 | — | — | — | |
| Merck & Co. Inc. | 4.08 | 2.96 | — | — | — | |
| Pfizer Inc. | 5.04 | 5.53 | — | — | — | |
| Regeneron Pharmaceuticals Inc. | 2.65 | 4.32 | — | — | — | |
| Thermo Fisher Scientific Inc. | 7.67 | 6.83 | — | — | — | |
| Vertex Pharmaceuticals Inc. | 3.55 | 4.64 | — | — | — | |
| Payables Turnover, Sector | ||||||
| Pharmaceuticals, Biotechnology & Life Sciences | 4.28 | 4.23 | — | — | — | |
| Payables Turnover, Industry | ||||||
| Health Care | 5.79 | 5.84 | — | — | — | |
Based on: 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31).
1 2022 Calculation
Payables turnover = Cost of revenues, exclusive of depreciation and amortization ÷ Accounts payable
= 9,382 ÷ 645 = 14.55
2 Click competitor name to see calculations.
An analysis of the operating activity from 2018 to 2022 reveals a consistent expansion in both the cost of revenues and the total volume of accounts payable. While the scale of operations has grown, the efficiency and timing of supplier payments have experienced distinct fluctuations over the five-year period.
- Growth in Procurement and Liabilities
- The cost of revenues, exclusive of depreciation and amortization, grew steadily from 6,746 million USD in 2018 to 9,382 million USD in 2022, with the most pronounced increase occurring between 2020 and 2021. Simultaneously, accounts payable rose from 437 million USD to 645 million USD, indicating an overall increase in the magnitude of short-term obligations to vendors.
- Payables Turnover Volatility
- The payables turnover ratio did not follow a linear path, starting at 15.44 in 2018 before dropping sharply to 12.70 in 2019. This ratio remained relatively flat in 2020 at 12.91, signifying a period where payments to suppliers were made less frequently compared to the 2018 baseline. A recovery was observed in 2021, with the ratio rising to 14.87, followed by a slight moderation to 14.55 in 2022.
- Working Capital Management Insights
- The decline in turnover observed between 2018 and 2020 suggests a strategic extension of payment terms, which typically allows a company to retain cash for longer periods. The subsequent increase in the turnover ratio in 2021 and 2022 indicates a return to a faster payment cycle. This shift suggests that despite the increase in the total volume of payables, the company accelerated its settlement of obligations toward the end of the period.
AI Ask an analyst for more
Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.
Without a user account, I tend to respond rather slowly.
How can I help you?
Working Capital Turnover
| Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | ||
|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | ||||||
| Current assets | 4,981) | 4,763) | 5,090) | 4,126) | 3,874) | |
| Less: Current liabilities | 5,578) | 5,241) | 4,558) | 3,945) | 3,534) | |
| Working capital | (597) | (478) | 532) | 181) | 340) | |
| Revenues | 14,410) | 13,874) | 11,359) | 11,088) | 10,412) | |
| Short-term Activity Ratio | ||||||
| Working capital turnover1 | — | — | 21.35 | 61.26 | 30.62 | |
| Benchmarks | ||||||
| Working Capital Turnover, Competitors2 | ||||||
| AbbVie Inc. | — | — | — | — | — | |
| Amgen Inc. | 3.82 | 3.37 | — | — | — | |
| Bristol-Myers Squibb Co. | 8.30 | 3.95 | — | — | — | |
| Danaher Corp. | 4.20 | 8.40 | — | — | — | |
| Eli Lilly & Co. | 31.84 | 8.33 | — | — | — | |
| Gilead Sciences Inc. | 8.42 | 8.54 | — | — | — | |
| Johnson & Johnson | — | 5.95 | — | — | — | |
| Merck & Co. Inc. | 5.16 | 7.62 | — | — | — | |
| Pfizer Inc. | 11.09 | 4.83 | — | — | — | |
| Regeneron Pharmaceuticals Inc. | 0.96 | 1.59 | — | — | — | |
| Thermo Fisher Scientific Inc. | 5.46 | 5.87 | — | — | — | |
| Vertex Pharmaceuticals Inc. | 0.85 | 1.02 | — | — | — | |
| Working Capital Turnover, Sector | ||||||
| Pharmaceuticals, Biotechnology & Life Sciences | 7.25 | 5.87 | — | — | — | |
| Working Capital Turnover, Industry | ||||||
| Health Care | 11.30 | 8.57 | — | — | — | |
Based on: 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31).
1 2022 Calculation
Working capital turnover = Revenues ÷ Working capital
= 14,410 ÷ -597 = —
2 Click competitor name to see calculations.
Revenue exhibited a consistent upward trajectory over the five-year period, increasing from US$ 10,412 million in 2018 to US$ 14,410 million by the end of 2022. This steady growth indicates a sustained expansion of the operational scale.
- Working Capital Dynamics
- Working capital experienced significant volatility, starting at US$ 340 million in 2018 and fluctuating before entering negative territory. A notable shift occurred between 2020 and 2021, where working capital dropped from US$ 532 million to negative US$ 478 million, further declining to negative US$ 597 million in 2022. This transition indicates a structural change where current liabilities began to exceed current assets.
- Working Capital Turnover Trends
- The turnover ratio showed extreme variance during the period for which calculations were provided. In 2019, the ratio peaked at 61.26, driven by a contraction in working capital relative to growing revenues. By 2020, the ratio declined to 21.35 as working capital increased. The lack of turnover ratios for 2021 and 2022 is a direct result of the shift to negative working capital, which renders the traditional turnover metric mathematically inapplicable for standard performance measurement.
The analysis reveals a fundamental transition in the operational funding model. While revenues grew steadily, the move toward negative working capital suggests a strategic shift. This pattern often indicates that a company is utilizing its current liabilities to finance its operations, which may reflect increased efficiency in the cash conversion cycle or a higher proportion of deferred revenue and supplier credit.
AI Ask an analyst for more
Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.
Without a user account, I tend to respond rather slowly.
How can I help you?
Average Receivable Collection Period
| Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | ||
|---|---|---|---|---|---|---|
| Selected Financial Data | ||||||
| Receivables turnover | 4.94 | 5.44 | 4.71 | 4.29 | 4.35 | |
| Short-term Activity Ratio (no. days) | ||||||
| Average receivable collection period1 | 74 | 67 | 77 | 85 | 84 | |
| Benchmarks (no. days) | ||||||
| Average Receivable Collection Period, Competitors2 | ||||||
| AbbVie Inc. | 71 | 65 | — | — | — | |
| Amgen Inc. | 82 | 74 | — | — | — | |
| Bristol-Myers Squibb Co. | 67 | 65 | — | — | — | |
| Danaher Corp. | 57 | 57 | — | — | — | |
| Eli Lilly & Co. | 88 | 86 | — | — | — | |
| Gilead Sciences Inc. | 65 | 61 | — | — | — | |
| Johnson & Johnson | 62 | 59 | — | — | — | |
| Merck & Co. Inc. | 58 | 69 | — | — | — | |
| Pfizer Inc. | 40 | 51 | — | — | — | |
| Regeneron Pharmaceuticals Inc. | 160 | 137 | — | — | — | |
| Thermo Fisher Scientific Inc. | 66 | 74 | — | — | — | |
| Vertex Pharmaceuticals Inc. | 59 | 55 | — | — | — | |
| Average Receivable Collection Period, Sector | ||||||
| Pharmaceuticals, Biotechnology & Life Sciences | 63 | 66 | — | — | — | |
| Average Receivable Collection Period, Industry | ||||||
| Health Care | 44 | 46 | — | — | — | |
Based on: 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31).
1 2022 Calculation
Average receivable collection period = 365 ÷ Receivables turnover
= 365 ÷ 4.94 = 74
2 Click competitor name to see calculations.
The analysis of short-term operating activity reveals fluctuations in the efficiency of receivables management between 2018 and 2022. A general trend of improving collection velocity is observed through 2021, followed by a moderate reversal in 2022.
- Receivables Turnover
- The turnover ratio demonstrated an overall upward trajectory for the majority of the period, increasing from 4.35 in 2018 to a peak of 5.44 in 2021. This progression indicates an enhanced ability to convert credit sales into cash. A subsequent decline to 4.94 was recorded in 2022, signaling a reduction in turnover efficiency relative to the 2021 peak.
- Average Receivable Collection Period
- The collection period exhibited an inverse correlation with the turnover ratio, decreasing from 84 days in 2018 to a low of 67 days in 2021. This reduction of 17 days suggests a significant optimization of credit collection processes or more stringent credit policies during that timeframe. In 2022, the collection period lengthened to 74 days, indicating a slight deterioration in the speed of cash recovery.
AI Ask an analyst for more
Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.
Without a user account, I tend to respond rather slowly.
How can I help you?
Average Payables Payment Period
| Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | ||
|---|---|---|---|---|---|---|
| Selected Financial Data | ||||||
| Payables turnover | 14.55 | 14.87 | 12.91 | 12.70 | 15.44 | |
| Short-term Activity Ratio (no. days) | ||||||
| Average payables payment period1 | 25 | 25 | 28 | 29 | 24 | |
| Benchmarks (no. days) | ||||||
| Average Payables Payment Period, Competitors2 | ||||||
| AbbVie Inc. | 61 | 60 | — | — | — | |
| Amgen Inc. | 90 | 77 | — | — | — | |
| Bristol-Myers Squibb Co. | 109 | 108 | — | — | — | |
| Danaher Corp. | 67 | 82 | — | — | — | |
| Eli Lilly & Co. | 106 | 83 | — | — | — | |
| Gilead Sciences Inc. | 58 | 39 | — | — | — | |
| Johnson & Johnson | 137 | 135 | — | — | — | |
| Merck & Co. Inc. | 89 | 123 | — | — | — | |
| Pfizer Inc. | 72 | 66 | — | — | — | |
| Regeneron Pharmaceuticals Inc. | 138 | 84 | — | — | — | |
| Thermo Fisher Scientific Inc. | 48 | 53 | — | — | — | |
| Vertex Pharmaceuticals Inc. | 103 | 79 | — | — | — | |
| Average Payables Payment Period, Sector | ||||||
| Pharmaceuticals, Biotechnology & Life Sciences | 85 | 86 | — | — | — | |
| Average Payables Payment Period, Industry | ||||||
| Health Care | 63 | 63 | — | — | — | |
Based on: 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31).
1 2022 Calculation
Average payables payment period = 365 ÷ Payables turnover
= 365 ÷ 14.55 = 25
2 Click competitor name to see calculations.
The analysis of short-term operating activity indicates a period of fluctuation in payables management between 2018 and 2022, ultimately returning to a state of stability closely aligned with the initial baseline.
- Payables Turnover
- A contraction in the turnover ratio occurred between 2018 and 2019, falling from 15.44 to 12.70. The ratio remained relatively stagnant in 2020 at 12.91 before experiencing a recovery to 14.87 in 2021 and settling at 14.55 in 2022. This movement indicates a temporary decrease in the frequency of supplier payments during the middle of the observed period.
- Average Payables Payment Period
- The duration required to settle obligations increased from 24 days in 2018 to a peak of 29 days in 2019. A subsequent downward trend is observed, with the period decreasing to 28 days in 2020 and further stabilizing at 25 days throughout 2021 and 2022. This pattern demonstrates a brief extension of payment terms followed by a return to a more accelerated payment cycle.
The inverse correlation between the turnover ratio and the payment period remains consistent across the five-year span. The convergence of the payment period toward 25 days by 2022 suggests that working capital management regarding supplier obligations has returned to a standardized operational rhythm.
AI Ask an analyst for more
Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.
Without a user account, I tend to respond rather slowly.
How can I help you?